We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04746066
Recruitment Status : Recruiting
First Posted : February 9, 2021
Last Update Posted : May 5, 2022
Sponsor:
Information provided by (Responsible Party):
Società Italiana Talassemie ed Emoglobinopatie

Tracking Information
First Submitted Date February 2, 2021
First Posted Date February 9, 2021
Last Update Posted Date May 5, 2022
Actual Study Start Date March 31, 2020
Estimated Primary Completion Date December 2030   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: February 8, 2021)
Number of Patients with Covid 19 infection [ Time Frame: through study completion, an average of 1 year ]
Incidence of Covid 19 infections in patient with Hemoglobinopathies and Rare Anemia inherit
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19
Official Title Observational Study Multicentric Phamacological no Profit for the Treatment of Patients With Hemoglobinopathies and Rare Inherited Anemia Affected by Covid 19
Brief Summary

The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic conditions are most affected by the SARS-COV2 infection. Infectious complications are a common cause of mortality and one of the main causes of morbidity in all these diseases. The main objective of this project is the assessment of patients with thalassemia, drepanocytosis, other haemoglobinopathies and rares inherited anemias suffering from SARS-COV-2 to:

  1. Obtain clinical and epidemiological data that can provide information on a possible increased vulnerability of these patients to SARS-COV-2 infection;
  2. Sharing therapeutic approaches considering the lack of information about the treatment.
Detailed Description

The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic diseases are most affected by SARS-COV2 infection. Italy is one of the countries most involved. Thalassaemia, drepanocytosis, other hemoglobinopathies and inherited anemias are widespread in italy and the mediterranean area. Thalassaemia syndromes are characterized by different clinical forms with mutations in globin genes that cause the reduction or complete absence of synthesis of the globin chain. Transfusion therapy remains the basis of thalassaemia management. Based on the extent of the severity of anemia and clinical presentation, thalassaemia was classified as transfusion-dependent (TDT) and non-transfusion-dependent (NTDT). Transfusion inevitably contributes to iron overload, which is associated with secondary morbidity, including organ damage, especially heart, liver, bone tissue, and endocrine glands. In ntdt, comorbility is mainly related to chronic anemia and increased gastrointestinal iron adsorption.

Other inherited anaemias include a large group of pathologies such as: hyporegenerative anaemias, such as congenital diseritropoietic anaemia and diamond-blackfan anemia; anaemies from deficiency of red blood cell membrane proteins due to altered membrane structure, such as hereditary spherocytosis and hereditary ellipsocytosis, and impaired membrane transport function, such as hereditary stomatocytosis; anaemies due to enzymatic deficiency, the most frequent of which are pyruvate deficiency kinase and glucose-6 phosphate dehydrogenase; sideroblastic anaemias and all other hereditary microcytic anaemies such as irida. All these anemias are characterized by high phenotypic heterogeneity but in most cases chronic hemolytic anemia, iron overload and addiction transfusion are found (as a percentage of a variable of cases). Transfusion therapy remains the basis of the management of these anaemias along with splenectomy (not practicable in all these classes of anemia). As with thalassaemia syndromes, in such anaemias, we find secondary morbidity, such as heart, liver, and endocrine damage resulting from both chronic anemia and iron overload.

Infectious complications are a common cause of mortality and one of the main causes of morbidity in all these pathologies. The greater quantitative and functional quantities, the involve t and b lymphocytes, production of immunoglobulins, neutrophils and macrophages, chemotaxis and phagocytosis, as well as the complement system. Excess iron can alter the immune balance in favour of the growth of infectious organisms. Other factors include multiple transfusions, associated with constant allo-antigenic stimulation. A large percentage of adult patients are splenectomized and risk complications related to splenectomy such as capsuled bacterial infections and immune system changes; low levels of zinc, another immune regulator; iron chelation therapy, which predisposes to serious yersinia-like infections. The circulation of abnormal erythrocytes is the cause of another permanent immune stimulus. In addition, particularly in elderly patients, the coexistence of adrenal hypofunction makes the response to sepsis less effective.

However, we have no information on the vulnerability of patients with thalassaemia, drepanocytosis, other hemoglobinopathies and hereditary anemias to SARS-COV2 infection. In order to obtain more information useful to increase our knowledge, a retrospective survey has been planned.

The main objective of this project is the evaluation of patients with thalassaemia, drepanocytosis, other hereditary hemoglobinopathies and anaemias affected by SARS-COV2 to:

  1. obtain clinical and epidemiological data that may dare information on a possible increased vulnerability of these patients to SARS-COV2;
  2. share therapeutic approaches considering the lack of information about treatment.

This is an italian study of observational, pharmacological, non-interventional, retrospective, prospective and multicenter, non-profit cohort. Patients diagnosed with thalassaemia, drepanocytosis, other hemoglobinopathies and hereditary anaemia positive to the SARS-COV2 virus will be enlisted. Patient data from reference centers will be introduced into the card via a web service.

The scientific committee of the project has discussed and approved a set of data that will be collected by local centers and that will feed the data collection database.

The study will be launched in every Italian center that requires participation. The Italian Society of Thalassaemia and Hemoglobinopathies (SITE) in its role as a scientific reporting company for pathology and the Foranemia Foundation, a non-profit organization, makes available to the center of microcitemie, coordinator of the study, a special web space for online data collection assuming the costs.

Study Type Observational
Study Design Observational Model: Other
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with an established diagnosis of thalassemia, sickle cell disease, other haemoglobinopathies and Rare Anemia inherit
Condition Haemoglobinopathies
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: February 8, 2021)
10000
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 2030
Estimated Primary Completion Date December 2030   (Final data collection date for primary outcome measure)
Eligibility Criteria

INCLUSION CRITERIA:

  • Patients with an established diagnosis of thalassemia, sickle cell disease, other haemoglobinopathies and Rare Anemia inherit with a virological diagnosis of SARS-COV-2 infection.

EXCLUSION CRITERIA:

  • nobody
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Gian Luca Forni 0105634 ext 560 gianluca.forni@galliera.it
Listed Location Countries Italy
Removed Location Countries  
 
Administrative Information
NCT Number NCT04746066
Other Study ID Numbers EMO AER COVID-19
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Undecided
Current Responsible Party Società Italiana Talassemie ed Emoglobinopatie
Original Responsible Party Same as current
Current Study Sponsor Società Italiana Talassemie ed Emoglobinopatie
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators
Principal Investigator: Gian Luca Forni Ospedali Galliera - SSD Microcitemia, anemie congenite e dismetabolismo del ferro
PRS Account Società Italiana Talassemie ed Emoglobinopatie
Verification Date May 2022